Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus

  • Fernández-Soto, Daniel
  • Bueno, P.
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Bueno, José L.
  • Duarte, Rafael F.
  • Jara, Ricardo
  • Valés-Gómez, Mar
  • Reyburn, H. T.
The membrane (M) glycoprotein of SARS-CoV-2 is one of the key viral proteins regulating virion assembly and morphogenesis. Immunologically, the M protein is a major source of peptide antigens driving T cell responses, and most individuals who have been infected with SARS-CoV-2 make antibodies to the N-terminal, surface-exposed peptide of the M protein. We now report that although the M protein is abundant in the viral particle, antibodies to the surface-exposed N-terminal epitope of M do not appear to neutralize the virus. M protein–specific antibodies do, however, activate antibody-dependent cell-mediated cytotoxicity and cytokine secretion by primary human natural killer cells. Interestingly, while patients with severe or mild disease make comparable levels of M antigen–binding antibodies, M-specific antibodies from the serum of critically ill patients are significantly more potent activators of antibody-dependent cell-mediated cytotoxicity than antibodies found in individuals with mild or asymptomatic infection., This work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028) and grants from Comunidad de Madrid (IMMUNOTHERCAN, S2017/BMD-3733-2 [M.V.-G.]), the Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) (MCIN/AEI/FEDER, EU: RTI2018-093569-B-I00, PID 2021-123795OB-I00 [both to M.V.-G.] and PID2020-115506RB-I00 [H.T.R.]). This research work was also funded by the European Commission—NextGenerationEU (Regulation EU 2020/2094), through the CSIC's Global Health Platform (PTI Salud Global). The Centro Nacional de Biotecnología also receives financial support from the Spanish State Research Agency (AEI/10.13039/501100011033) through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). D.F.S. is a recipient of a fellowship (PRE2018-083200) from the Spanish Ministry of Science and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease

  • Fernández-Soto, Daniel
  • García-Jiménez, Álvaro Fernando
  • Casasnovas, José María
  • Valés-Gómez, Mar
  • Reyburn, H. T.
[Introduction]: It is now clear that coronavirus disease 19 (COVID-19) severity is associated with a dysregulated immune response, but the relative contributions of different immune cells is still not fully understood. SARS CoV-2 infection triggers marked changes in NK cell populations, but there are contradictory reports as to whether these effector lymphocytes play a protective or pathogenic role in immunity to SARS-CoV-2., [Methods]: To address this question we have analysed differences in the phenotype and function of NK cells in SARS-CoV-2 infected individuals who developed either very mild, or life-threatening COVID-19 disease., [Results]: Although NK cells from patients with severe disease appeared more activated and the frequency of adaptive NK cells was increased, they were less potent mediators of ADCC than NK cells from patients with mild disease. Further analysis of peripheral blood NK cells in these patients revealed that a population of NK cells that had lost expression of the activating receptor NKG2D were a feature of patients with severe disease and this correlated with elevated levels of cell free NKG2D ligands, especially ULBP2 and ULBP3 in the plasma of critically ill patients. In vitro, culture in NKG2DL containing patient sera reduced the ADCC function of healthy donor NK cells and this could be blocked by NKG2DL-specific antibodies., [Discussion]: These observations of reduced NK function in severe disease are consistent with the hypothesis that defects in immune surveillance by NK cells permit higher levels of viral replication, rather than that aberrant NK cell function contributes to immune system dysregulation and immunopathogenicity., This work was supported by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028)]; the Spanish Ministry of Science and Innovation (MCIU/AEI/FEDER, EU) [Ministerio de Ciencia, Innovación y Universidades (MCIU)/Agencia Estatal de Investigación (AEI)/European Regional Development Fund (FEDER, EU): PID2021-123795OB-I00 (MVG) and PID2020-115506RB-I00 (HTR)].] This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through the CSIC’s Global Health Platform (PTI Salud Global). The CNB also acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). DF is a recipient of a fellowship (PRE2018-083200) from the Spanish Ministry of Science and Innovation. ÁG-J is a recipient of a fellowship (FPU18/01698) from the Spanish Ministry of Science and Education. Both are graduate students in the Molecular Biosciences doctoral program of the Autonomous University of Madrid., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals

  • Albert, Eliseo
  • Fernández-Soto, Daniel
  • Giménez, Estela
  • Casanovas, José María
  • Zulaica, Joao
  • Álvarez-Rodríguez, Beatriz
  • Rusu, Luciana
  • Geller, Ron
  • Reyburn, H. T.
  • Navarro, David
Antibodies triggering Fc-mediated NK cell activity may contribute to protection against disease caused by SARS-CoV-2 infection in humans. However, how these Fc-mediated humoral responses compare between individuals displaying hybrid immunity (Vac-ex) and those fully vaccinated with no history of SARS-CoV-2 infection (Vac-n) and whether they correlate with neutralizing antibody (NtAb) responses remains largely undetermined. In this retrospective study serum samples from 50 individuals (median age, 44.5 years; range, 11–85; 25 males), 25 Vac-ex and 25 Vac-n were studied. A flow-cytometry-based antibody-mediated NK-cell activation assay was used to quantitate effector NK-cells stimulated to express LAMP1 (lysosomal associated membrane protein 1), MIP1 (Macrophage inflammatory protein 1), and interferon-γ (IFNγ); NK cells isolated from two donors (D1 and D2) were used. NtAb levels targeting the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants were quantitated using a SARS-CoV-2 S pseudotyped neutralization assay. Regardless of the SARS-CoV-2 variant S antigen used in the NK-cell activation assay, the frequency of NK cells stimulated to express LAMP-1, MIP1β, and IFNγ was higher in Vac-ex compared with Vac-n (p values ranging from 0.07 to 0.006) for D1; this was only seen for BA.1 when NK cells from D2 were employed. The frequency of functional NK cells activated by antibody binding to either Wuhan-Hu-1 or Omicron BA.1 S protein was not significantly different for both VAC-ex and VAC-n. In contrast, NtAb titers against BA.1 were around 10-fold lower than that against Wuhan-Hu-1. Vac-ex displayed higher NtAb titers against both (sub)variants than Vac-n. NK-cell responses correlated poorly with NtAb titers (ρ ≤ 0.30). The data demonstrate higher cross-reactivity across variants of concern for antibodies triggering Fc-mediated NK cell than for NtAb. Moreover, Vac-Ex seemed to display more robust functional antibody responses as compared with Vac-n., Estela Giménez (Juan Rodés Contract, JR18/00053) and Eliseo Albert (Juan Rodés Contract; JR20/00011) hold contracts funded by the Carlos III Health Institute (co-financed by the European Regional Development Fund, ERDF/FEDER). Beatriz Álvarez-Rodríguez holds a Generalitat Valenciana postdoctoral fellowship (APOSTD/2021/017). This study was supported by Instituto de Salud Carlos III, Madrid, Spain (FIS, PI21/00563) granted to David Navarro, and by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028) and a grant from the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): PID2020-115506RB-I00 (HTR)]. The CNB also acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the “Severo Ochoa” Program for Centers of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). Daniel Fernández Soto is a recipient of a fellowship (PRE2018-083200) from the Spanish Ministry of Science and Innovation and is a graduate student in the Molecular Biosciences doctoral program of the Autonomous University of Madrid. This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through the CSIC's Global Health Platform (PTI Salud Global) to Ron Geller and Hugh Reyburn. The funders had no role in study design, data collection and interpretation, or in the decision to submit the work for publication., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functional antibody responses targeting the Spike protein of SARS-CoV-2 Omicron XBB.1.5 in elderly nursing home residents following Wuhan-Hu-1-based mRNA booster vaccination

  • Sánchez-Simarro, Ángela
  • Fernández-Soto, Daniel
  • Grau, Brayan
  • Albert, Eliseo
  • Giménez, Estela
  • Avilés-Alía, Ana Isabel
  • Gozalbo-Rovira, Roberto
  • Rusu, Luciana
  • Olea, Beatriz
  • Geller, Ron
  • Reyburn, H. T.
  • Navarro, David
The immune effector mechanisms involved in protecting against severe COVID-19 infection in elderly nursing home residents following vaccination or natural infection are not well understood. Here, we measured SARS-CoV-2 Spike (S)-directed functional antibody responses, including neutralizing antibodies (NtAb) and antibody Fc-mediated NK cell activity (degranulation and IFNγ production), against the Wuhan-Hu-1, BA.4/5 (for NtAb), and Omicron XBB.1.5 variants in elderly nursing home residents (n = 39; median age, 91 years) before and following a third (pre- and post-3D) and a fourth (pre- and post-4D) mRNA COVID-19 vaccine dose. Both 3D and 4D boosted NtAb levels against both (sub)variants. Likewise, 3D and 4D increased the ability of sera to trigger both LAMP1- and IFNγ-producing NK cells, in particular against XBB.1.5. In contrast to NtAb titres, the frequencies of LAMP1- and IFNγ-producing NK cells activated by antibodies binding to Wuhan-Hu-1 and Omicron XBB.1.5 S were comparable at all testing times. Stronger functional antibody responses were observed in vaccine-experienced participants compared to vaccine-naïve at some testing times. These findings can contribute to identifying a reliable correlate of protection in elderly nursing home residents against severe COVID-19 and inform future vaccine strategies in this population group., Ángela Sánchez-Simarro has a contract funded by the Carlos III Health Institute (PFIS Contract; FI22/00338). Eliseo Albert holds a contract funded by the Carlos III Health Institute (co-financed by the European Regional Development Fund, ERDF/FEDER): Juan Rodés Contract; JR20/00011. Brayan Grau is supported by a Juan de la Cierva postdoctoral fellowship (FJC2021-046453-I). This study was supported by the Instituto de Salud Carlos III, Madrid, Spain (FIS, PI21/00563) granted to David Navarro, by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC-COVID19-028), and a grant from the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): PID2020-115506RB-I00 (HTR)]. The CNB also acknowledges financial support from the Spanish State Research Agency, AEI/https://doi.org/10.13039/501100011033, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-2017-0712). D. Fernández Soto is a recipient of a fellowship (PRE2018-083200) from the Spanish Ministry of Science and Innovation and is a graduate student in the Molecular Biosciences doctoral program of the Autonomous University of Madrid. This research work was also funded by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through the CSIC's Global Health Platform (PTI Salud Global) to Ron Geller and Hugh Reyburn., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Estimating SARS-CoV-2 omicron XBB.1.5 spike-directed functional antibody levels from an anti-receptor binding domain Wuhan-Hu-1-based commercial immunoassay results

  • Sánchez-Simarro, Ángela
  • Cuevas-Ferrando, Enric
  • Fernández-Soto, Daniel
  • Grau, Brayan
  • Albert, Eliseo
  • Giménez, Estela
  • Avilés-Alía, Ana Isabel
  • Rusu, Luciana
  • Geller, Ron
  • Reyburn, H. T.
  • Navarro, David
We investigated whether antibody concentrations measured in plasma using the Roche Elecsys® Anti-SARS-CoV-2 S assay (targeting the receptor binding domain, RBD) could estimate levels of Wuhan-Hu-1 and Omicron XBB.1.5 spike-directed antibodies with neutralizing ability (NtAb) or those mediating NK-cell activity. We analyzed 135 plasma samples from 39 vaccinated elderly nursing home residents. A strong correlation was found for NtAb against both Wuhan-Hu-1 (Rho = 0.73, p < 0.001) and Omicron XBB.1.5 (sub)variants (Rho = 0.73, p < 0.001). Moderate positive correlations were observed for NK-cell activity, based on lysosome-associated membrane protein 1 (LAMP1)-producing NK cells stimulated with Wuhan-Hu-1 (Rho = 0.43, p < 0.001) and Omicron XBB.1.5 spike proteins (Rho = 0.50, p < 0.001). Similarly, interferon-gamma (IFN-γ)-producing NK-cell frequencies showed moderate correlations (Wuhan-Hu-1: Rho = 0.43, p < 0.001; Omicron XBB.1.5: Rho = 0.50, p < 0.001). Random Forest models accurately predicted NtAb levels against Wuhan-Hu-1 (R2 = 0.72), though models for Omicron XBB.1.5 were less robust. Anti-RBD antibody concentrations of 4.73 and 5.02 log10 BAU/mL predicted high NtAb levels for Wuhan-Hu-1 and Omicron XBB.1.5, respectively. Antibody thresholds for predicting functional NK cell-mediated responses were 4.73 log10 and 4.54 log10 BAU/mL for Wuhan-Hu-1 and Omicron XBB.1.5, respectively. For LAMP1-producing NK cells, the thresholds were 4.94 and 4.75 log10 BAU/mL for Wuhan-Hu-1 and Omicron XBB.1.5, respectively. In summary, total anti-RBD antibody levels measured by the Roche assay may allow inference of NtAb levels and, to a lesser extent, Fc-mediated NK-cell responses against Omicron XBB.1.5., Ángela Sánchez‐Simarro has a contract funded by the Carlos III Health Institute (PFIS Contract; FI22/00338). Eliseo Albert holds a contract funded by the Carlos III Health Institute (co‐financed by the European Regional Development Fund, ERDF/FEDER): Juan Rodés Contract; JR20/00011. Brayan Grau is supported by a Juan de la Cierva postdoctoral fellowship (FJC2021‐046453‐I). This study was supported by the Instituto de Salud Carlos III, Madrid, Spain (FIS, PI21/00563) granted to David Navarro, by the Spanish National Research Council (CSIC, project numbers 202020E079 and CSIC‐COVID19‐028), and a grant from the Spanish Ministry of Science and Innovation [(MCIU/AEI/FEDER, EU): PID2020‐115506RB‐I00 (HTR)]. D. Fernández Soto is a recipient of a fellowship (PRE2018‐083200) from the Spanish Ministry of Science and Innovation and is a graduate student in the Molecular Biosciences doctoral program of the Autonomous University of Madrid. The CNB also acknowledges financial support from the Spanish State Research Agency, AEI/10.13039/501100011033, through the“Severo Ochoa” Programme for Centres of Excellence in R&D (SEV‐2013‐0347, SEV‐2017‐0712). This research work was also funded by the European Commission– NextGenerationEU (Regulation EU 2020/2094), through the CSIC's Global Health Platform (PTI Salud Global) to Ron Geller and Hugh Reyburn. The funders had no role in study design, data collection, and interpretation, or in the decision to submit the work for publication., Peer reviewed